-+ 0.00%
-+ 0.00%
-+ 0.00%

Jazz says FDA approves Ziihera combos for first-line HER2+ advanced gastroesophageal cancer

PUBT·08/31/2026 10:01:57
Listen to the news
Jazz says FDA approves Ziihera combos for first-line HER2+ advanced gastroesophageal cancer
  • Jazz Pharmaceuticals said the FDA cleared Ziihera with tislelizumab and chemotherapy for first-line HER2+ unresectable locally advanced or metastatic GEA.
  • The agency also cleared Ziihera with chemotherapy in the same setting for HER2+ IHC 3+ disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608310600PR_NEWS_USPR_____SF36593) on August 31, 2026, and is solely responsible for the information contained therein.